Cargando…
A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma
Immune checkpoint inhibitor (CPI) therapy is approved for the treatment of many cancers. As its use becomes more prevalent, sequential trials with different CPIs as monotherapy or combination therapy will become more common. It is thought that the increased cumulative dose of CPIs over multiple tria...
Autores principales: | Singh, Vinit, Chu, Yvonne, Gupta, Varsha, Zhao, Charlie Weige |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331908/ https://www.ncbi.nlm.nih.gov/pubmed/32637277 http://dx.doi.org/10.7759/cureus.8395 |
Ejemplares similares
-
Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia
por: Alqahtani, Ali, et al.
Publicado: (2023) -
Hypernatremia in Diabetic Ketoacidosis: Rare Presentation and a Cautionary Tale
por: Ibarra, Gabriel, et al.
Publicado: (2020) -
A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
por: Bazzi, Talal, et al.
Publicado: (2022) -
Myriad Manifestations of 3-Beta-Hydroxysteroid Dehydrogenase 2 Deficiency—A Tale of Two Infants
por: Hathi, Deep, et al.
Publicado: (2022)